Treatment shows promise in patients with lung condition

Sotatercept may be effective in treating patients with a recent diagnosis of pulmonary arterial hypertension.

In a phase III trial published in The New England Journal of Medicine, researchers randomly assigned 320 patients with pulmonary arterial hypertension (within the first year after diagnosis) to receive subcutaneous administration of sotatercept or placebo every three weeks as an addition to standard therapy.

After a median follow-up of 13 months, the researchers found that sotatercept was capable of reducing the risk of clinical worsening by more than 75% and lengthening the six-minute walk distance by a median of 13 meters. While deterioration of exercise performance and unplanned hospitalization for worsening disease occurred less frequently among the patients of the sotatercept group, overall adverse events were more common in those who received sotatercept.

The findings indicated that sotatercept could be effective in partially addressing the underlying causes of pulmonary arterial hypertension.

Read more: The New England Journal of Medicine

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.